Phaseline

Companies › Immunovant Sciences

Immunovant Sciences: clinical trials, targets and expected readouts

2 active drug programs in 7 registered trials: 6 Phase 2, 1 Phase 3; Neurology, Immunology, Metabolic and endocrine; next expected readout Apr 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
IMVT-1402–Phase 3Generalized Myasthenia Gravis; Subacute Cutaneous Lupus Erythematosus; Graves' Disease; Rheumatoid Arthritis …Apr 2027
Imeroprubart
FcγRIIB-FcαRI fusion protein; neonatal Fc receptor (FcRn) inhibitor
FCARPhase 2Chronic Inflammatory Demyelinating PolyneuropathyAug 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06980805IMVT-1402Phase 2Subacute Cutaneous Lupus ErythematosusImmunologyApr 2027
NCT07018323IMVT-1402Phase 2Graves' DiseaseMetabolic and endocrineMay 2027
NCT06754462IMVT-1402Phase 2Rheumatoid ArthritisImmunologySep 2027
NCT07039916IMVT-1402Phase 3Generalized Myasthenia GravisNeurologyDec 2027
NCT06727604IMVT-1402Phase 2Graves' DiseaseMetabolic and endocrineJun 2028
NCT06979531IMVT-1402Phase 2Primary Sjögren's SyndromeImmunologyJul 2028
NCT07032662ImeroprubartPhase 2Chronic Inflammatory Demyelinating PolyneuropathyNeurologyAug 2028

From the company's SEC filings

Cash of $722m on 2026-09-30; operating cash outflow about $416m a year; runway about 21 months at that burn, to Jun 2028; 5 of 6 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Private offerings reported to the SEC (Form D)

Targets

FCAR (1)

Companies with the same targets

argenx

Companies built like this

Oculis Coya Therapeutics NervGen Pharma Cognition Therapeutics Immunic

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.